Novo Nordisk (NYSE: NVO) reported earnings on Feb. 3, leading to a decline in stock value. The company had disappointing 2026 guidance, with sales and earnings expected to drop by 5-13%. However, the positive news includes strong adoption of the new GLP-1 pill, with 170,000 patients using it after four weeks.

The drop in Novo Nordisk’s stock price can be attributed to lower pricing on GLP-1 drugs in the U.S. market. Despite the challenges, the company’s CEO remains optimistic, stating that results may dip before rebounding. The shift to a pill format opens up a larger market, potentially increasing demand.

Despite the recent setbacks, Novo Nordisk remains an important player in the GLP-1 space. The company’s early success with the GLP-1 pill suggests a potential offset to the pricing hit in 2026. Management anticipates a positive outlook post-2026, focusing on increasing volume to drive growth.

The Motley Fool Stock Advisor team does not recommend Novo Nordisk as one of the top 10 stocks to buy now. However, historical data shows significant returns from past recommendations. Consider joining Stock Advisor for access to their latest recommendations and join a community of individual investors.

Investors should note that Novo Nordisk’s stock price has declined significantly since 2024. Despite this, the company’s focus on GLP-1 drugs and the potential for increased demand from the new pill format offer hope for future growth. Management expects volume to offset pricing challenges in the long term.

Read more at Yahoo Finance: Novo Nordisk Plunges Nearly 15% After Earnings. Here’s What Investors Need to Know.